AN2 Therapeutics, Inc. Profile Avatar - Palmy Investing

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous …

Biotechnology
US, Menlo Park [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

AN2 Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ANTX's Analysis
CIK: 1880438 CUSIP: 037326105 ISIN: US0373261058 LEI: - UEI: -
Secondary Listings
ANTX has no secondary listings inside our databases.